semaglutide thyroid cancer decelerates the growth and progression of breast by enhancing the acquired antitumor immunity medullary thyroid cancer and semaglutide

Vias, P., Martnez-Castillo, N., Campillo, N

[8] The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, with no new safety signals over a mean follow-up of 34.2 months

For select patients, lower-dose semaglutide or tirzepatide protocols may be used to support appetite regulation, craving reduction, metabolic flexibility and body composition maintenance

Peptides may be lower-risk in some situations because they often stimulate natural hormone pathways rather than directly replacing hormones